Key result
Prophylactic beta-blockers or ACEi/ARBs preserve LVEF by ~3 to 5 points during anthracycline chemotherapy.
Why the study?
Chemotherapy-induced cardiotoxicity and left ventricular dysfunction impair prognosis, making prevention crucial.
Does prophylactic treatment with beta-blockers or ACE inhibitors/ARBs prevent the decrease in left ventricular ejection fraction in cancer patients receiving anthracycline-based chemotherapy?
Meta-Analysis (n=1,350)
Does prophylactic treatment with beta-blockers or ACE inhibitors/ARBs prevent the decrease in left ventricular ejection fraction in cancer patients receiving anthracycline-based chemotherapy?
Prophylactic use of beta-blockers or ACE inhibitors/ARBs offers a moderate but statistically significant attenuation of left ventricular ejection fraction decline in cancer patients exposed to cardiotoxic anthracycline chemotherapy.
Answers are grounded in this paper and cite their sources.
Supports prophylactic neurohormonal blockade to modestly attenuate anthracycline cardiotoxicity; extends randomized.
AIMS: Conventional cytotoxic chemotherapy is still among the most effective treatment options for many types of cancer. However, cardiotoxicity, notably the decrease in left ventricular function under these regimens, can impair prognosis. Thus, prevention and treatment of cardiotoxicity are crucial. The present meta-analysis aims to assess the efficacy of beta-blockers or angiotensin-converting enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARBs) for prevention of cardiotoxicity. METHODS AND RESULTS: We systematically searched Pubmed, Cochrane, EMBASE, and Web of Science databases for randomized controlled trials published until February 2019. The analysis included randomized studies that reported on left ventricular ejection fraction (LVEF) after 6 months of chemotherapy in cancer patients who received beta-blockers or ACE inhibitors/ARBs for prevention of cardiotoxicity compared with controls. Studies on combination cardioprotective therapies were excluded from the analysis. The primary endpoint was prevention of a decrease in LVEF as defined by the individual study and as assessed by either transthoracic echocardiography or magnetic resonance imaging. We here show that patients under anthracycline-based chemotherapy have a moderate yet significant benefit in LVEF from beta-blockers or ACEs/ARBs. The beta-blocker analysis included 769 cancer patients, and the ACE inhibitors/ARBs analysis included a total of 581 cancer patients. The mean LVEF difference between the beta-blocker group and the control group was 2.57% (95% confidence interval 0.63-4.51, P = 0.009). The mean difference for ACE inhibitors/ARBs was 4.71% (95% confidence interval 0.38-9.03, P = 0.03). However, the beneficial effects throughout the studies were variable as documented by significant heterogeneity between the studies. CONCLUSIONS: Systematic evidence is needed to solidly found recommendations for cardioprotective prevention during chemotherapy. Likewise, trials on other neurohumoral drugs (spironolactone) and lipid-lowering approaches are required to improve protection for cardio-oncology patients.
No takes yet. Share an insight, caveat, or question.
Totzeck et al. (2019) conducted a meta-analysis in Cancer undergoing anthracycline-based chemotherapy (n=1,350). Beta-blockers or ACE inhibitors/ARBs vs. Control without cardioprotective therapy was evaluated on Prevention of a decrease in LVEF after 6 months of chemotherapy (beta-blocker vs control analysis) (MD 2.57%, 95% CI 0.63-4.51, p=0.009). Prophylactic use of beta-blockers or ACE inhibitors/ARBs significantly preserved left ventricular ejection fraction with mean differences of 2.57% and 4.71%, respectively, compared to controls in cancer patients receiving anthracycline-based chemotherapy.
Synapse has enriched 10 related papers. Consider them for comparative context: